Method for producing a non-human animal model of uterine cancer, a non-human animal model of uterine cancer, and a method for evaluating a test substance

By introducing loss-of-function mutations into the PTEN, LKB1, and Tp53 genes in uterine epithelial cells using a nucleic acid editing module, the method addresses the limitations of existing uterine cancer model mice, enabling efficient production of a non-human animal model that accurately represents uterine cancer.

JP7812112B2Active Publication Date: 2026-02-09GUNMA UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
JP2021189718
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-11-22
Publication Date
2026-02-09
Estimated Expiration
2041-11-22

AI Technical Summary

Technical Problem

Existing uterine cancer model mice require prior genomic DNA modification and are not capable of reproducing the actual disease due to mutations occurring post-sexual maturity, making them cumbersome to create and less representative of human uterine cancer.

Method used

A method to produce a non-human animal model of uterine cancer by introducing loss-of-function mutations into the PTEN, LKB1, and Tp53 genes in uterine epithelial cells using a nucleic acid editing module, allowing for the development of uterine cancer from wild-type animals.

Benefits of technology

Enables the production of a non-human animal model of uterine cancer from wild-type animals, improving the representation and efficiency of uterine cancer modeling without the need for prior genomic DNA modification.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide a method for producing a model mouse of endometrial cancer that can be prepared even from a wild-type mouse .SOLUTION: A method for producing a uterine cancer model nonhuman animal disclosed herein includes a mutation step for bringing the genome DNA of a uterine epithelial cell of a nonhuman animal into contact with a nucleic acid editing module for inducing a loss-of-function mutation in a target gene, wherein the target gene includes PTEN gene and liver kinase B1(LKB1) gene.SELECTED DRAWING: Figure 5
Need to check novelty before this filing date? Find Prior Art